TNFRSF17 and cancer: Thus, it is becoming imperative to predict which CAR construct will be most effective for a given cancer patient, and which patient will be a responder in a particular CAR treatment or ’off-the-shelf’ immune products (e.g., blinatumomab and anti-BCMA x anti-CD3 BITE agents).